Literature DB >> 15494950

The role of Shiga-toxin-producing Escherichia coli in hemorrhagic colitis and hemolytic uremic syndrome.

Thomas G Cleary1.   

Abstract

The Shiga-toxin-producing E. coli represent a major class of pathogens that have been defined over the last twenty years. They cause distinctive clinical manifestations such as afebrile bloody diarrhea with severe abdominal pain (hemorrhagic colitis) and microangiopathic hemolytic anemia with renal failure (hemolytic uremic syndrome). The most common Shiga-toxin-producing E. coli is serotype O157:H7, although at least one hundred different serotypes share the virulence traits and clinical manifestations with this organism. Understanding the pathophysicology, improving diagnostic tools, and developing a treatment strategy are important areas of ongoing investigations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15494950     DOI: 10.1053/j.spid.2004.07.007

Source DB:  PubMed          Journal:  Semin Pediatr Infect Dis        ISSN: 1045-1870


  9 in total

1.  Rapid and sensitive detection of Shiga toxin-producing Escherichia coli from nonenriched stool specimens by real-time PCR in comparison to enzyme immunoassay and culture.

Authors:  Thomas E Grys; Lynne M Sloan; Jon E Rosenblatt; Robin Patel
Journal:  J Clin Microbiol       Date:  2009-05-13       Impact factor: 5.948

2.  Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia.

Authors:  Paola Marcato; Thomas P Griener; George L Mulvey; Glen D Armstrong
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

3.  Bovine colostral antibody against verotoxin 2 derived from Escherichia coli O157:H7: resistance to proteases and effects in beagle dogs.

Authors:  Takashi Kuribayashi; Tetsuro Seita; Mariko Matsumoto; Katsunori Furuhata; Kazutoshi Tagata; Shizuo Yamamoto
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

4.  Implications of screening and childcare exclusion policies for children with Shiga-toxin producing Escherichia coli infections: lessons learned from an outbreak in a daycare centre, Norway, 2012.

Authors:  Emily MacDonald; Per Kjetil Dalane; Preben Aavitsland; Lin Thorstensen Brandal; Astrid Louise Wester; Line Vold
Journal:  BMC Infect Dis       Date:  2014-12-18       Impact factor: 3.090

5.  Analysis of individual patient data to describe the incubation period distribution of Shiga-toxin producing Escherichia coli.

Authors:  A Awofisayo-Okuyelu; I Hall; E Arnold; L Byrne; N McCarthy
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

6.  Properties of an Antimicrobial Molecule Produced by an Escherichia coli Champion.

Authors:  Sarah-Jo Paquette; Tim Reuter
Journal:  Antibiotics (Basel)       Date:  2019-12-21

Review 7.  Haemolytic-uraemic syndrome as a sequela of diarrhoeal disease.

Authors:  Christa L Fischer Walker; Jennifer A Applegate; Robert E Black
Journal:  J Health Popul Nutr       Date:  2012-09       Impact factor: 2.000

8.  Modulation of neutrophil function by a secreted mucinase of Escherichia coli O157:H7.

Authors:  Rose L Szabady; Mary A Lokuta; Kevin B Walters; Anna Huttenlocher; Rodney A Welch
Journal:  PLoS Pathog       Date:  2009-02-27       Impact factor: 6.823

9.  Quantitative surveillance of shiga toxins 1 and 2, Escherichia coli O178 and O157 in feces of western-Canadian slaughter cattle enumerated by droplet digital PCR with a focus on seasonality and slaughterhouse location.

Authors:  Sarah-Jo Paquette; Kim Stanford; James Thomas; Tim Reuter
Journal:  PLoS One       Date:  2018-04-12       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.